Basel Medical Group Ltd filings document its foreign private issuer reporting, Nasdaq listing-rule compliance, governance changes and corporate transactions. Form 6-K current reports cover periodic-filing compliance, minimum bid price notifications, board and executive appointments or resignations, and changes in the company's independent registered public accounting firm.
The company's SEC disclosures also record financing-related lock-up waivers, Form 20-F reporting matters, and the completed acquisition of Bethesda Medical as a wholly owned indirect subsidiary. These filings provide formal disclosure on the company's Singapore healthcare operations, capital-structure actions, audit oversight, governance structure and material events affecting its listed ordinary shares.
Basel Medical Group Ltd (BMGL) identifies Xinwen Yang as a director in an initial statement of beneficial ownership.
Basel Medical Group Ltd (BMGL) closed a registered direct offering of 6,000,000 units at US$1.33 per unit on October 9, 2026, generating US$7.98 million in gross proceeds and estimated net proceeds of approximately US$7.28 million. Each unit included one ordinary share and one Common Warrant to buy one ordinary share; no Pre-Funded Warrants were issued. The company intends to use all net proceeds for working capital, mergers and acquisitions, and other general corporate purposes.
Ordinary shares outstanding increased from 1,582,111 immediately before the offering to 7,582,111 immediately after closing; 6,000,000 Common Warrants were also issued. The warrants are immediately exercisable at 110% of the unit offering price and expire five years from issuance. If all are exercised on a zero-cash basis, 6,000,000 additional ordinary shares would be issued without additional cash to the company. The company, its executive officers and directors, and certain shareholders beneficially owning 5.0% or more before the offering are subject to 180-day lock-up restrictions, subject to exceptions and placement-agent consent provisions.
Basel Medical Group Ltd (BMGL) entered into a placement agency agreement with Cathay Securities, Inc., as placement agent, and a securities purchase agreement with certain purchasers to issue and sell 6,000,000 units in a registered direct offering at a public offering price of US$1.33 per Unit. Each unit consists of one ordinary share or one Pre-Funded Warrant, plus one Common Warrant to purchase one ordinary share. Gross proceeds will be US$7.98 million before commissions and offering expenses; estimated net proceeds are approximately US$7.28 million for working capital, mergers and acquisitions, and other general corporate purposes.
Common Warrants are exercisable immediately at 110% of the public offering price per Unit and expire five years after issuance. After closing and within the exercise period, holders may use a zero-cash option; if all 6,000,000 are exercised that way, 6,000,000 additional ordinary shares would be issued without additional cash to the company. Units containing a Pre-Funded Warrant are priced US$0.01 below the final Unit offer price, and each Pre-Funded Warrant has a US$0.01-per-share exercise price. Subject to limited exceptions, exercise is restricted if a holder and affiliates would exceed 4.99% beneficial ownership; a holder may elect to increase the limit up to 9.99%. Ordinary shares outstanding were 1,582,111 immediately before the offering and will total 7,582,111 upon completion.
Basel Medical Group Ltd (BMGL) is conducting a best-efforts public offering of up to 6,000,000 units at US$1.33 per Unit. Each unit comprises one ordinary share or one pre-funded warrant for one ordinary share, plus one common warrant for one ordinary share. A unit including a pre-funded warrant is priced US$0.01 below the final Unit offer price. BMGL is also registering up to 6,000,000 ordinary shares underlying each warrant type. Common warrants are immediately exercisable at 110% of the Unit price, expire five years after issuance, and may be exercised for no additional payment under a zero-cash option; pre-funded warrants have a US$0.01 exercise price. Both warrant types have a 4.99% beneficial-ownership limit, which may be increased up to 9.99% at the holder’s election.
BMGL estimates net proceeds of approximately US$7.28 million if all units are sold, for working capital, mergers and acquisitions, and other general corporate purposes. The offering has no minimum sale condition, and actual proceeds may be substantially lower; delivery is expected on or about October 9, 2026, subject to customary closing conditions. If all common warrants are exercised through the zero-cash option, up to 6,000,000 shares would be issued without additional payment to BMGL, resulting in substantial dilution. Ordinary shares outstanding were 1,582,111 as of October 7, 2026.
Basel Medical Group Ltd (BMGL) identifies Frederick Shieh Ming Hong as a director and reporting person in a Form 3.
Basel Medical Group Ltd (BMGL) is registering up to 6,000,000 units, plus up to 6,000,000 ordinary shares underlying each of the pre-funded and common warrants, in a best-efforts offering. The listed price is US$1.33 per unit; units containing a pre-funded warrant are priced US$0.01 below the final Unit offer price. Each unit contains one ordinary share or one pre-funded warrant for a share, plus one common warrant for a share. There is no minimum sale requirement.
If all units are sold, BMGL estimates net proceeds of approximately US$7.37 million after placement-agent fees and estimated offering expenses, for working capital, mergers and acquisitions, and other general corporate purposes. Zero-cash exercise of all common warrants could issue up to 6,000,000 shares without additional cash to the company. Nasdaq notified BMGL on July 8, 2026, that it had regained minimum bid-price compliance after a 1-for-12 reverse split effective June 22, 2026.
Basel Medical Group Ltd (BMGL) is conducting a best-efforts primary offering of up to 6,000,000 Units, each consisting of one ordinary share (or one pre-funded warrant in lieu of a share) and one common warrant, and is also registering up to 6,000,000 ordinary shares underlying the pre-funded warrants and up to 6,000,000 ordinary shares underlying the common warrants. The Units are priced within a yet-to-be-determined U.S. dollar range per Unit and will be sold through Cathay Securities, Inc. as placement agent, with no minimum offering amount.
Basel Medical, a BVI holding company for a Singapore-based network of orthopedic, trauma, sports medicine, neurosurgical and general practice clinics, had 1,582,111 ordinary shares outstanding before the offering and would have 7,582,111 shares outstanding immediately after the sale of all Units, excluding any warrant exercises. The common warrants include a zero cash exercise price option, so up to an additional 6,000,000 shares could be issued without bringing in further cash, creating potential substantial dilution. Net proceeds are intended for general working capital, mergers and acquisitions, and other corporate purposes.
Basel Medical Group Ltd (BMGL) reports board changes. Directors Fung Keng Leong (Raymond) and Tan Boon Chye (Darren) have stepped down from the board with immediate effect, while Darren Tan continues as chief commercial officer. Three new directors have joined the board: Yang Xinwen, Cao Juan, and Frederick Hong Shieh Ming, who becomes an independent director. The company states that none of the new directors currently have beneficial ownership of its shares. The new appointees bring experience in healthcare, business development, operations, capital markets, and real estate advisory, which the company believes will strengthen strategic leadership, corporate governance, and support its next phase of business development and growth.